Ilya Pharma have had a successful preIND meeting with the FDA related to the development of ILP100-Oral
News
Abstract selected for poster presentation at International Society for Cell- and Gene Therapy 2023 London May 2023
Abstract: The Value of early Regulatory Interactions with Authorities for emilimogene sigulactibac (INN) - a new modality in gene therapy, to be presented by Margareth Jorvid Head of Regulatory Affairs
Ilya Pharma will participate at AMWC 2023 - 21st Aesthetic & Anti-Aging Medicine World Congress
Ilya Pharma will present company updates at BioFuture hosted live in NYC 7-8 November and virtually 14-16 November
Conference topic is to - Reimagine the future of therapeutics
Ilya Pharma appoints Leo Groenewegen as CEO of recent acquisition Nordic Bioanalysis
Bioprocessing and analytics industry business expert to spearhead major growth drive
Ilya Pharma presents poster at US Military Health System Research Symposium in Florida September 12
Dr Andreas Fasth, Head of Clinical Developments and Medical Affairs at Ilya Pharma is on site and presenting "Accelerated wound healing by on-site production and delivery of CXCL12 by transformed lactic acid bacteria in 36 healthy volunteers with experimentally induced wounds".
Labiotech.eu reports on Ilya Pharmas latest new patents covering major markets
Ilya Pharma, a Swedish clinical stage biopharma company focused on delivering local immunotherapies to patients, has announced the issue of four new patents.